Publications
191 results found
Gotch FM, Imami N, Hardy G, 2001, Candidate vaccines for immunotherapy in HIV., HIV Med, Vol: 2, Pages: 260-265, ISSN: 1464-2662
In this short article we review the immunopathology of HIV infection and delineate the kinds of immune responses seen in acute infection and in long-term nonprogression that are understood to be necessary if the host is to maintain long-term control of the virus. In this context we discuss the potential promise of therapeutic vaccination in HIV infection.
Tchilian EZ, Wallace DL, Dawes R, et al., 2001, A point mutation in CD45 may be associated with an increased risk of HIV-1 infection, AIDS, Vol: 15, Pages: 1892-1894
Pido-Lopez J, Imami N, Aspinall R, 2001, Both age and gender affect thymic output: more recent thymic migrants in females than males as they age, CLINICAL AND EXPERIMENTAL IMMUNOLOGY, Vol: 125, Pages: 409-413, ISSN: 0009-9104
- Author Web Link
- Cite
- Citations: 139
Imami N, Hardy G, Gotch F, 2001, Development of immunotherapeutic strategies for HIV-1, EXPERT OPINION ON BIOLOGICAL THERAPY, Vol: 1, Pages: 803-816, ISSN: 1471-2598
- Author Web Link
- Cite
- Citations: 11
Imami N, Hardy G, Pires A, et al., 2001, Detection and quantification of HIV-1 specific CD4 helper and CD8 cytotoxic cells: their role in HIV-1-infected individuals and vaccine recipients., HIV Med, Vol: 2, Pages: 146-153, ISSN: 1464-2662
There is a strong link between virus specific CD8 T-cell function and the efficiency of regulatory CD4 helper T cells. Controlling viraemia in HIV-1-infected individuals requires the maintenance of strong CD4 and CD8 T-cell responses. These responses should be elicited by prophylactic vaccination and by postexposure immunotherapy. This review will examine the methods that are available for the detection and quantification of HIV-1 specific CD4 and CD8 T-cell responses. We will also discuss the methods that should be used to identify these responses in HIV-1-infected individuals, seropositive recipients of immunotherapy and seronegative vaccinees. Finally, we will give examples of how responses observed in vitro relate to those known to occur in vivo.
Gotch FM, Imami N, 2001, Outcomes of a trial of HIV-1 immunogen in patients with HIV infection., JAMA, Vol: 285, Pages: 2191-2192, ISSN: 0098-7484
Dat NV, 2001, Outcomes of a trial of HIV-1 immunogen in patients with HIV infection., JAMA, Vol: 285, ISSN: 0098-7484
Tchilian EZ, Wallace DL, Imami N, et al., 2001, The exon A (C77G) mutation is a common cause of abnormal CD45 splicing in humans., J. Immunol, Vol: 166, Pages: 6144-6148
Hardy GAD, Imami N, Sullivan AK, et al., 2000, Immunomodulation in HIV-1 infection: Building on the benefits of highly active anti-retroviral therapy (HAART), Annual Congress of the British Society for Immunology, ISSN: 0019-2805
Pires ALGS, Pozniak A, Nelson M, et al., 2000, Immune restoration disease in HIV-1 infected patients on HAART: Cell mediated immune responses and immunophenotype, Annual Congress of the British Society for Immunology, ISSN: 0019-2805
Sullivan AK, Pires ALGS, Hardy GAD, et al., 2000, Evaluation of the effects of highly active antiretroviral therapy (HAART) in HIV-1 infected patients: A phenotypical analysis, Annual Congress of the British Society for Immunology, ISSN: 0019-2805
Burton CT, Sullivan AK, Hardy GAD, et al., 2000, Assessment of beta chemokines and IL-16 in HIV-1 infected individuals: Impact of antiretroviral therapy, Annual Congress of the British Society for Immunology, ISSN: 0019-2805
Sullivan AK, Imami N, Hardy GAD, et al., 2000, Acute viral load blips in response to subcutaneous interleukin-2 therapy in HIV-1 infected individuals on highly active antiretroviral therapy, AIDS, Vol: 14, Pages: S73-S74, ISSN: 0269-9370
Sullivan AK, Pires A, Hardy GAD, et al., 2000, Phenotypic T cell changes in HIV-1 infected individuals receiving highly active antiretroviral therapy, AIDS, Vol: 14, Pages: S75-S75, ISSN: 0269-9370
Wilson JDK, Imami N, Watkins A, et al., 2000, Loss of CD4<SUP>+</SUP> T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease, JOURNAL OF INFECTIOUS DISEASES, Vol: 182, Pages: 792-798, ISSN: 0022-1899
- Author Web Link
- Cite
- Citations: 105
Imami N, Aspinall R, Gotch F, 2000, Role of the thymus in T lymphocyte reconstitution, TRANSPLANTATION, Vol: 69, Pages: 2238-2239, ISSN: 0041-1337
- Author Web Link
- Cite
- Citations: 5
Gotch F, Rutebemberwa A, Jones G, et al., 2000, Vaccines for the control of HIV/AIDS, Trop Med Int Health, Vol: 5, Pages: A16-A21, ISSN: 1360-2276
This review discusses the feasibility of an HIV vaccine and describes the history, efficacy and potential to succeed of old and new vaccine concepts.
Wilson JDK, Imami N, Gil J, et al., 1999, HIV-1-induced intracellular cytokines and lymphoproliferative responses in long term non-progressors and individuals with progressive HIV-1 infection, Joint Congress of the British Society for Immunology and the British Society for Allergy and Clinical Immunology., ISSN: 0019-2805
Imami N, Antonopoulos C, Hardy GAD, et al., 1999, Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: Impact of highly active antiretroviral therapy, AIDS RESEARCH AND HUMAN RETROVIRUSES, Vol: 15, Pages: 1499-1508, ISSN: 0889-2229
- Author Web Link
- Cite
- Citations: 76
Imami N, Hardy GAD, Nelson MR, et al., 1999, Induction of HTV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy, CLINICAL AND EXPERIMENTAL IMMUNOLOGY, Vol: 118, Pages: 78-86, ISSN: 0009-9104
- Author Web Link
- Cite
- Citations: 37
Gotch F, Hardy G, Imami N, 1999, Therapeutic vaccines in HIV.1 infection, IMMUNOLOGICAL REVIEWS, Vol: 170, Pages: 173-182, ISSN: 0105-2896
- Author Web Link
- Cite
- Citations: 20
Marelli-Berg FM, Frasca L, Imani N, et al., 1999, Lack of T cell proliferation without induction of nonresponsiveness after antigen presentation by endothelial cells, TRANSPLANTATION, Vol: 68, Pages: 280-287, ISSN: 0041-1337
- Author Web Link
- Cite
- Citations: 20
Imami N, Ladyman HM, Vincents B, et al., 1998, K21-antigen: a molecule shared by the microenvironments of the human thymus and germinal centers, Developmental Immunology, Vol: 6, Pages: 41-52, ISSN: 1044-6672
The mouse IgG1 monoclonal antibody (mAb) K21 recognizes a 230-kD molecule (K21-Ag) on Hassall's corpuscles in the human thymus. This mAb also stains cultured thymic epithelial cells as well as other epithelial cell lines, revealing a predominant intracellular localization. Further analysis with mAb K21 on other lymphoid tissues showed that it also stains cells within the germinal centers of human tonsils, both lymphoid (B) cells and some with the appearance of follicular dendritic cells. Double immunostaining of tonsil sections shows that K21-Ag is not expressed by T cells, whereas staining with anti-CD22 and -CD23 mAb revealed some doublepositive cells. A subpopulation of the lymphoid cells express the K21-Ag much more strongly. This K21++/CD23++ subpopulation of cells is localized in the apical light zone of germinal centers, suggesting that K21-Ag may be an important marker for the selected centrocytes within germinal centers and may play a role in B-cell selection and/or development of B-cell memory. Flow cytometric analysis showed that K21-Ag is expressed on the surface of a very low percentage of thymocytes, tonsillar lymphocytes, and peripheral blood mononuclear cells. Analysis of purified/separated tonsillar T and B lymphocytes showed that T cells do not express the K21-Ag; in contrast, B cells express low levels of the K21-Ag, and this together with CD23 is upregulated after mitogenic stimulation. Our data therefore raise the possibility that the K2l- Ag may play a role in B-lymphocyte activation/selection.
Imami N, Hardy G, Morris-Jones S, et al., 1998, Combination of highly active antiretroviral drugs and cytokines as salvage therapy in advanced HIV-1 disease: Shift from a type-2 to type-1 cytokine environment, 6th Annual Congress of the British Society for Immunology, ISSN: 0019-2805
McKay PF, Imami N, Johns M, et al., 1998, The gp200-MR6 molecule which is functionally associated with the IL-4 receptor modulates B cell phenotype and is a novel member of the human macrophage mannose receptor family, EUROPEAN JOURNAL OF IMMUNOLOGY, Vol: 28, Pages: 4071-4083, ISSN: 0014-2980
- Author Web Link
- Cite
- Citations: 33
Gotch FM, Imami N, Hardy GA, et al., 1998, The effects of antiviral therapy on the immune system, AIDS, Vol: 12, Pages: S3-S3, ISSN: 0269-9370
Obi A, Imami N, Gotch F, et al., 1998, Cytomegalovirus retinitis in AIDS patients with persistently low CD4 counts receiving HAART, Association for Research in Vision and Ophthalmology annual meeting, Publisher: Association for Research in Vision and Ophthalmology, ISSN: 1552-5783
Imami N, Brookes PA, Lombardi G, et al., 1998, Association between interleukin-4-producing T lymphocyte frequencies and reduced risk of graft-versus-host disease, TRANSPLANTATION, Vol: 65, Pages: 979-988, ISSN: 0041-1337
- Author Web Link
- Cite
- Citations: 19
Frasca L, Marelli-Berg F, Imami N, et al., 1998, Interferon-γ-treated renal tubular epithelial cells induce allospecific tolerance, KIDNEY INTERNATIONAL, Vol: 53, Pages: 679-689, ISSN: 0085-2538
- Author Web Link
- Cite
- Citations: 58
Marelli-Berg FM, Weetman A, Frasca L, et al., 1997, Antigen presentation by epithelial cells induces anergic immunoregulatory CD45RO<SUP>+</SUP> T cells and deletion of CD45RA<SUP>+</SUP> T cells, JOURNAL OF IMMUNOLOGY, Vol: 159, Pages: 5853-5861, ISSN: 0022-1767
- Author Web Link
- Cite
- Citations: 69
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.